PT3265568T - Terapias de aumento de genes para a degeneração hereditária da retina causada por mutações no gene prpf31 - Google Patents

Terapias de aumento de genes para a degeneração hereditária da retina causada por mutações no gene prpf31

Info

Publication number
PT3265568T
PT3265568T PT167623073T PT16762307T PT3265568T PT 3265568 T PT3265568 T PT 3265568T PT 167623073 T PT167623073 T PT 167623073T PT 16762307 T PT16762307 T PT 16762307T PT 3265568 T PT3265568 T PT 3265568T
Authority
PT
Portugal
Prior art keywords
gene
mutations
prpf31
retinal degeneration
degeneration caused
Prior art date
Application number
PT167623073T
Other languages
English (en)
Original Assignee
Massachusetts Eye & Ear Infirmary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Eye & Ear Infirmary filed Critical Massachusetts Eye & Ear Infirmary
Publication of PT3265568T publication Critical patent/PT3265568T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/22Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/008Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
PT167623073T 2015-03-06 2016-03-07 Terapias de aumento de genes para a degeneração hereditária da retina causada por mutações no gene prpf31 PT3265568T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562129638P 2015-03-06 2015-03-06
US201562147307P 2015-04-14 2015-04-14

Publications (1)

Publication Number Publication Date
PT3265568T true PT3265568T (pt) 2020-08-20

Family

ID=56879585

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167623073T PT3265568T (pt) 2015-03-06 2016-03-07 Terapias de aumento de genes para a degeneração hereditária da retina causada por mutações no gene prpf31

Country Status (15)

Country Link
US (2) US20180043034A1 (pt)
EP (2) EP3265568B1 (pt)
JP (3) JP6812368B2 (pt)
CY (1) CY1123158T1 (pt)
DK (1) DK3265568T3 (pt)
ES (1) ES2806054T3 (pt)
HK (1) HK1247637A1 (pt)
HR (1) HRP20201225T1 (pt)
HU (1) HUE051491T2 (pt)
LT (1) LT3265568T (pt)
PL (1) PL3265568T3 (pt)
PT (1) PT3265568T (pt)
RS (1) RS60668B1 (pt)
SI (1) SI3265568T1 (pt)
WO (1) WO2016144892A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
RU2611202C2 (ru) 2011-04-22 2017-02-21 Те Риджентс Оф Те Юниверсити Оф Калифорния Вирионы аденоассоциированного вируса с вариантным капсидом и способы их использования
JP6600624B2 (ja) 2013-05-31 2019-10-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アデノ随伴ウイルス変異体及びその使用方法
US10000741B2 (en) 2014-03-17 2018-06-19 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
BR112017018846A2 (pt) 2015-03-02 2018-07-31 Adverum Biotechnologies, Inc. composições e métodos para entrega intravítrea de polinucleotídeos a cones retinianos.
HUE051491T2 (hu) * 2015-03-06 2021-03-01 Massachusetts Eye & Ear Infirmary Gén-augmentációs terápiák a PRPF31 gén mutációi által okozott öröklött retina degenerációra
CN107532177A (zh) * 2015-03-24 2018-01-02 加利福尼亚大学董事会 腺相关病毒变体及其使用方法
WO2018022905A2 (en) 2016-07-29 2018-02-01 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
CN110225975A (zh) 2016-08-23 2019-09-10 阿库斯股份有限公司 用于治疗人受试者中非年龄相关的听力损害的组合物和方法
EP3528785A4 (en) 2016-10-19 2020-12-02 Adverum Biotechnologies, Inc. MODIFIED AAV CASPIDS AND USES THEREOF
CA3061968A1 (en) * 2017-05-10 2018-11-15 Massachusetts Eye And Ear Infirmary Methods and compositions for modifying assembly-activating protein (aap)-dependence of viruses
CA3059995A1 (en) 2017-08-28 2019-03-07 The Regents Of The University Of California Adeno-associated virus capsid variants and methods of use thereof
EP3802836A4 (en) * 2018-06-01 2022-10-19 University of Florida Research Foundation, Incorporated COMPOSITIONS AND METHODS FOR THE TREATMENT OF DOMINANT RETINITIS PIGMENTOSA
WO2020102740A2 (en) * 2018-11-16 2020-05-22 Spark Therapeutics, Inc. Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
BR112022016596A2 (pt) 2020-02-21 2022-11-16 Akouos Inc Composições e métodos para o tratamento de debilitação auditiva não associada à idade em um indivíduo humano

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023787A1 (de) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
EP0228458B2 (en) 1985-07-05 1997-10-22 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
DE3852823T2 (de) 1987-09-11 1995-05-24 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
DE3851153T2 (de) 1987-12-11 1995-01-05 Whitehead Biomedical Inst Genetische modifizierung von endothelialen zellen.
EP0732397A3 (en) 1988-02-05 1996-10-23 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
EP0452457B1 (en) 1989-11-03 1997-08-20 Vanderbilt University Method of in vivo delivery of functioning foreign genes
EP0556345B2 (en) 1990-10-31 2005-10-12 Cell Genesys, Inc. Retroviral vectors useful for gene therapy
ES2150832B1 (es) 1996-06-12 2001-06-16 Fichtel & Sachs Ag Dispositivo de maniobra para la maniobra, en particular maniobra neumatica, de un embrague de friccion.
US6569662B1 (en) * 2000-01-21 2003-05-27 Hyseq, Inc. Nucleic acids and polypeptides
CA2442670A1 (en) * 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
US20040208847A1 (en) * 2003-03-28 2004-10-21 Fabienne Rolling Method and vectors for selectively transducing retinal pigment epithelium cells
EP1991701A4 (en) * 2006-02-14 2010-03-17 Dana Farber Cancer Inst Inc COMPOSITIONS, KITS, AND METHODS FOR IDENTIFYING, EVALUATING, PREVENTING, AND TREATING CANCER
ES2907452T3 (es) * 2007-04-12 2022-04-25 The Provost Fellows Found Scholars & The Other Members Of Board Of The College Of The Holy & Undiv T Supresión y reemplazo genético
WO2008137066A1 (en) * 2007-05-02 2008-11-13 The Board Of Regents Of The University Of Oklahoma Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
WO2009134681A2 (en) * 2008-04-30 2009-11-05 The Trustees Of The University Of Pennsylvania Aav7 viral vectors for targeted delivery of rpe cells
WO2010005533A2 (en) * 2008-06-30 2010-01-14 The Johns Hopkins University Compositions and methods for the treatment of ocular oxidative stress and retinitis pigmentosa
GB201103062D0 (en) * 2011-02-22 2011-04-06 Isis Innovation Method
TWI702955B (zh) * 2012-05-15 2020-09-01 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
EP2872183B1 (en) * 2012-07-11 2018-09-26 The Trustees Of The University Of Pennsylvania Aav-mediated gene therapy for rpgr x-linked retinal degeneration
JP6552511B2 (ja) 2013-10-11 2019-07-31 マサチューセッツ アイ アンド イヤー インファーマリー 祖先ウイルス配列を予測する方法およびその使用
EP3154573A1 (en) * 2014-06-13 2017-04-19 Universidade De Santiago De Compostela Nanoparticulate systems for use in gene transfer or gene delivery
HUE051491T2 (hu) 2015-03-06 2021-03-01 Massachusetts Eye & Ear Infirmary Gén-augmentációs terápiák a PRPF31 gén mutációi által okozott öröklött retina degenerációra

Also Published As

Publication number Publication date
CY1123158T1 (el) 2021-10-29
HRP20201225T1 (hr) 2020-11-13
PL3265568T3 (pl) 2020-11-30
US20180043034A1 (en) 2018-02-15
EP3265568A1 (en) 2018-01-10
EP3265568B1 (en) 2020-05-06
ES2806054T3 (es) 2021-02-16
EP3265568A4 (en) 2018-08-08
DK3265568T3 (da) 2020-08-10
EP3748007A1 (en) 2020-12-09
HUE051491T2 (hu) 2021-03-01
WO2016144892A1 (en) 2016-09-15
LT3265568T (lt) 2020-08-25
JP2018511652A (ja) 2018-04-26
HK1247637A1 (zh) 2018-09-28
JP2023071867A (ja) 2023-05-23
SI3265568T1 (sl) 2020-10-30
JP7239550B2 (ja) 2023-03-14
US20210069347A1 (en) 2021-03-11
RS60668B1 (sr) 2020-09-30
JP2021059561A (ja) 2021-04-15
JP6812368B2 (ja) 2021-01-13

Similar Documents

Publication Publication Date Title
HK1247637A1 (zh) 因prpf31基因突變所導致的遺傳性視網膜退化的基因增強治療
IL252442A0 (en) Combined treatments
IL251468A0 (en) aav-based gene therapy
GB201512869D0 (en) Gene signature for minute therapies
PL3722274T3 (pl) Związki semifluorowane
EP3364997A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM BALANCE IN NEURODEEGENERATIVE DISEASES
IL284577A (en) Garden healing
GB201507781D0 (en) Blending techniques for curve fitting
HK1258518A1 (zh) 用於眼病的基因療法
GB201420139D0 (en) Factor IX gene therapy
ZA201704793B (en) Treatment of retinal degeneration using progenitor cells
HK1243598A1 (zh) 聯合治療
GB201407322D0 (en) Gene therapy
HK1249834A1 (zh) 容器裝小麥粉
EP3708680B8 (en) Compositions and methods for xi chromosome reactivation
HK1219810A1 (zh) 在生物相容性通電元件中使用的陽極
EP3307306A4 (en) GENE EXPRESSION IN BACTEROIDS
EP3209131A4 (en) Compositions and methods for treatment with hemopexin
GB201513151D0 (en) Functional gene replacement therapy
PT3722274T (pt) 2-perfluorobutilpentano para administração oftálmica
GB201503246D0 (en) Online health audit
PL3165235T3 (pl) Białka do stosowania do zwalczania ptaszyńców kurzych
SG10201912076UA (en) Gene therapy composition
AU2015904270A0 (en) ParkShare online app
AU2015902698A0 (en) Online marketplace